medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2013, Number 607

<< Back Next >>

Rev Med Cos Cen 2013; 70 (607)

Miocardiopatía periparto

Méndez RE

Language: Spanish
References: 23
Page: 449-455
PDF size: 455.80 Kb.


ABSTRACT

Peripartum cardiomyopathy is idiopathic heart failure occurring in the absence of any determinable heart disease during the last month of pregnancy or the first 5 months postpartum. The incidence varies worldwide but is high in developing nations; the cause of the disease might be a combination of environmental and genetic factors. The prevalence of mutations associated with familial dilated cardiomyopathy genes in patients with peripartum cardiomyopathy suggests an overlap in the clinical spectrum of these 2 diseases. Treatment for peripartum cardiomyopathy includes conventional pharmacologic heartfailure therapies.Targeted therapies (such as intravenous immunoglobulin, pentoxifylline, and bromocriptine) have shown promise in small trials but require further evaluation. Fortunately, despite a mortality rate of up to 10% and a high risk of relapse in subsequent pregnancies, many patients with peripartum cardiomyopathy recover within 3 to 6 months of disease onset.


REFERENCES

  1. Anderson JL, Horne BD. Birthing the genetics of peripartum cardiomyopathy. Circulation 2010; 121:2157–9.

  2. Bozkurt B, Villaneuva FS, Holubkov R, et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 1999;34:177– 80.

  3. Campos O. Doppler echocardiography during pregnancy. Echocardiography. 1996; 13:135-46.

  4. Demakis JG, Rahimtoola SH, Sutton GC, et al. Natural course of peripartum cardiomyopathy. Circulation 1971; 44:1053– 61.

  5. Elkayam U, Akhter, MW, Singh H, et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation 2005; 11:2050 –5.

  6. Elkayam U, Tummala PP, Rao K, Akhter MW, Karaalp IS, Wani OR, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy

  7. Felker GM, Jaeger CJ, Klodas E, Thiemann DR, Hare JM, Hruban RH, et al. Myocarditis and long-term survival in peripartum cardiomyopathy. Am Heart J 2000; 140(5):785-91.

  8. Fett JD, Sannon H, Thelisma E, Sprunger T, Suresh V. Recovery from severe heart failure following peripartum cardiomyopathy. Int J Gynaecol Obstet 2009; 104(2):125-7.

  9. Gouley BA, McMillan TM, Bellet S. Idiopathic myocardial degeneration associated with pregnancy and especially the puerperium. Am J Med Sci 1937;194:185–99.

  10. Hibbard JU, Lindheimer M, Lang R. A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography. Obstet Gynecol 1999; 94:311– 6.

  11. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation [published erratum appears in Circulation 2010; 121(12):e258]. Circulation 2009; 119(14):e391-479.

  12. Meijboom LJ, Vos FE, Timmermans J, Beers GH, Zwinderman AH, Mulder Bj. Pregnancy and aortic root growth in the Marfan syndrome: a prospective study. Eur Heart J. 2005; 26:914-20.

  13. Mindy B. Gentry, James K. Dias. African-American Women have a higher Risk for Developing Peripartum Cardiomyopathy. Journal of the American College of Cardiology 2010; 654-659.

  14. Morales A, Painter T, Li R et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation 2010; 121:2176–82.

  15. Pearson GD, Veille JC, Rahimtoola S et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 2000; 283:1183– 8.

  16. Pijuan, Antonia. 2006. “enfermedades cardiovasculares de la mujer; (embarazo y cardiopatía)”. Revista española de cardiología.

  17. Siu S, Sermer M, Harrison D, Grigoriadis E, Liu G, Sorensen S, et al. Risk and predictors for pregnancy-related complications in women with heart disease. Circulation. 1997; 96:2789-94.

  18. Siu S, Sermer S, Colman J, Álvarez N,Mercier L, Morton B, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation. 2001; 104:515-21.

  19. Sliwa K, Forster O, Libhaber E, Fett JD, Sundstrom JB, Hilfiker-Kleiner D, Ansari AA. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 2006; 27 (4):441-6.

  20. Sliwa K, Hilfiker -Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12:767–78.

  21. Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, Sareli P. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail 2002;4(3):305-9.

  22. Tanous D, Siu SC, Mason J, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol 2010; 56: 1247–53.

  23. Van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation 2010; 121:2169 –75.




2020     |     www.medigraphic.com